Scholarlink

Background <p>Tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) typically polarize toward an M2 phenotype that promotes tumor progression and immune suppression. Reprogramming TAMs to the proinflammatory M1 phenotype has emerged as a promising strategy to boost antitumor immunity. This study aimed to develop a targeted nanoplatform to deliver small activating RNAs (saRNAs) that upregulate genes involved in macrophage reprogramming.</p> Results <p>We designed saRNAs targeting the promoters of p38 and TFEB, encapsulated within a metal-organic framework (MOF)-based delivery system and cloaked with hybrid membranes composed of synthetic lipids and exosome-derived vesicles. These were further functionalized with the TAM-targeting peptide CRV (CRVLRSGSC), resulting in nanoparticles termed CLMSR. CLMSR selectively accumulated in macrophages, enhancing intracellular saRNA delivery. Functional assays revealed that conditioned medium from CLMSR-treated M2 macrophages suppressed tumor cell migration, invasion, and 3D spheroid formation. In vivo, CLMSR demonstrated prolonged circulation time and enhanced tumor targeting. Importantly, treatment remodeled the TME by increasing CD8⁺ and CD4⁺ T cell infiltration and promoting TAM repolarization from the M2 to M1 phenotype.</p> Conclusions <p>Our findings demonstrate that CLMSR represents a novel and efficient nanoplatform for saRNA delivery to reprogram TAMs and modulate the TME. By targeting M2 macrophages and inducing their transition to the tumoricidal M1 phenotype, this approach offers a promising therapeutic avenue to enhance antitumor immunity and inhibit tumor progression.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biomimetic proteolipid vesicles delivering small activating RNA to activate the macrophage immunotherapy for the treatment of lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月16日

查看全文
  • Hui Yu,
  • Jiandong Zhang,
  • Qiuyun Liu,
  • Ling Liu,
  • Yingying Le,
  • Huiyu Cen,
  • Weijie Peng,
  • Juyan Wei,
  • Sijia Liu,
  • Aiping Qin,
  • Yuyan Qin,
  • Xiufeng Li,
  • XiaoGang Xu,
  • Lingmin Zhang,
  • Lu Liang

摘要

Background

Tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) typically polarize toward an M2 phenotype that promotes tumor progression and immune suppression. Reprogramming TAMs to the proinflammatory M1 phenotype has emerged as a promising strategy to boost antitumor immunity. This study aimed to develop a targeted nanoplatform to deliver small activating RNAs (saRNAs) that upregulate genes involved in macrophage reprogramming.

Results

We designed saRNAs targeting the promoters of p38 and TFEB, encapsulated within a metal-organic framework (MOF)-based delivery system and cloaked with hybrid membranes composed of synthetic lipids and exosome-derived vesicles. These were further functionalized with the TAM-targeting peptide CRV (CRVLRSGSC), resulting in nanoparticles termed CLMSR. CLMSR selectively accumulated in macrophages, enhancing intracellular saRNA delivery. Functional assays revealed that conditioned medium from CLMSR-treated M2 macrophages suppressed tumor cell migration, invasion, and 3D spheroid formation. In vivo, CLMSR demonstrated prolonged circulation time and enhanced tumor targeting. Importantly, treatment remodeled the TME by increasing CD8⁺ and CD4⁺ T cell infiltration and promoting TAM repolarization from the M2 to M1 phenotype.

Conclusions

Our findings demonstrate that CLMSR represents a novel and efficient nanoplatform for saRNA delivery to reprogram TAMs and modulate the TME. By targeting M2 macrophages and inducing their transition to the tumoricidal M1 phenotype, this approach offers a promising therapeutic avenue to enhance antitumor immunity and inhibit tumor progression.

Graphical abstract